How much revenue does Acepodia make?

Acepodia reported 185,000 TWD in revenue for fiscal year 2025, down 56.7% from 427,000 TWD in fiscal year 2024.

What companies are similar to Acepodia?

Listed companies of a similar size in the same industry (additional cancer treatment drugs) include Foresee Pharmaceuticals Co., Ltd. (6576.TWO), Taho Pharma (6467.TWO), PharmaEngine, Inc. (4162.TWO), Shine-On BioMedical Co.,Ltd. (6926.TWO).

Acepodia, Inc. (6976.TWO) Stock

About Acepodia, Inc.

Acepodia, Inc. operates as a clinical stage biotechnology company. The company engages in developing cell therapies with its antibody cell conjugation (ACC) platform technology to address cancer care. It develops AD2C targeting GPC3 for HCC which is in preclinical stage; ACE 1831 targeting CD20 that is in phase 1 clinical trial; The company is based in Grand Cayman, the Cayman Islands.

At a glance

Acepodia reported revenue of 185,000 TWD for fiscal year 2025, down 56.7% from fiscal year 2024, and net income of -754.40 million TWD.

Figures from company filings; latest fiscal year ended December 31, 2025.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.